CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report)’s stock price rose 8.3% during mid-day trading on Thursday . The company traded as high as $2.45 and last traded at $2.41. Approximately 5,716 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 35,527 shares. The stock had previously closed at $2.23.
Analyst Ratings Changes
Separately, Benchmark reissued a “speculative buy” rating and issued a $5.00 price target on shares of CytoMed Therapeutics in a research report on Thursday, October 10th.
Read Our Latest Stock Report on GDTC
CytoMed Therapeutics Price Performance
CytoMed Therapeutics Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Read More
- Five stocks we like better than CytoMed Therapeutics
- Comparing and Trading High PE Ratio Stocks
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- How to Buy Cheap Stocks Step by Step
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
